Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection

Inclusion Criteria

• •1. Male and female patients aged from 18 to 65 years.
• •2. According to the routine clinical practice, a patient is scheduled to receive the treatment as per one of the following regimens:
• •\- Basic therapy of ARVI1 + Cycloferone®.
• •* Basic therapy of ARVI1 + Arbidol®.
• •3. Presence of symptoms of ARVI:
• •* Presence of two and more symptoms of moderate severity or three and more mild symptoms in accordance with the WURSS-21 questionnaire;
• •* Presence of two and more symptoms of moderate severity or three and more mild symptoms in accordance with the CCQ questionnaire;
• •* Presence of hyperthermia episodes ≥ 37.5°С and ≤ 40.0°С from onset of the disease.
• •<!-- -->
• •1. Male and female patients aged from 18 to 65 years.
• •2. According to the routine clinical practice, a patient is scheduled to receive the treatment as per one of the following regimens:
• •\- Basic therapy of ARVI1 + Cycloferone®.
• •\- Basic therapy of ARVI1 + Arbidol®.
• •3. Presence of symptoms of ARVI:
• •\- Presence of two and more symptoms of moderate severity or three and more mild symptoms in accordance with the WURSS-21 questionnaire;
• •* Presence of two and more symptoms of moderate severity or three and more mild symptoms in accordance with the CCQ questionnaire;
• •* Presence of hyperthermia episodes ≥ 37.5°С and ≤ 40.0°С from onset of the disease.
• •4. Diagnosis as per ICD-10 (primary diagnosis is one of the below diagnoses):
• •\- J00 - Acute nasopharyngitis, rhinitis;
• •\- J02 - Acute pharyngitis;
• •\- J02.8 - Acute pharyngitis caused by other specified pathogens;
• •\- J02.9 - Acute pharyngitis, not otherwise specified;
• •\- J03 - Acute tonsillitis;
• •\- J03.8 - Acute tonsillitis caused by other specified pathogens;
• •\- J02.9 - Acute tonsillitis, not otherwise specified;
• •\- J04 - Acute laryngitis and tracheitis;
• •\- J04.0 - Acute laryngitis;
• •\- J04.1 - Acute tracheitis;
• •\- J04.2 - Acute laryngotracheitis;
• •\- J05 - Acute obstructive laryngitis (croup);
• •\- J05.0 - Acute obstructive laryngitis (croup);
• •\- J06 - Acute infection of the upper respiratory tract of multiple and unspecified localization;
• •\- J06.0 - Acute laryngopharyngitis;
• •\- J06.8 - Other acute infections of the upper respiratory tract of multiple localization;
• •\- J06.9 - Acute infection of the upper respiratory tract, not otherwise specified;
• •\- J20.4 - Acute bronchitis caused by parainfluenza virus;
• •\- J20.5 - Acute bronchitis caused respiratory syncitial virus;
• •\- J20.6 - Acute bronchitis caused by rhinovirus;
• •\- J20.8 - Acute bronchitis caused by other specified agents;
• •\- J20.9 - Acute bronchitis, not otherwise specified;
• •\- J21 - Acute bronchiolitis;
• •\- J21.0 - Acute bronchiolitis caused by respiratory syncytial virus;
• •\- J21.8 - Acute bronchiolitis caused by other specified agents;
• •\- J21.9 - Acute bronchiolitis, not otherwise specified;
• •\- J22 - Acute respiratory infection of lower respiratory tract, not otherwise specified;
• •\- B34.0 - Adenovirus infection, not otherwise specified;
• •\- B34.9 - Viral infection, not otherwise specified;
• •\- B97.0 - Adenovirus infection;
• •* B97.4 - Respiratory syncytial infection.
• •5. Symptoms of the disease are present for not more than 24 h before inclusion in the study.
• •6. Patient's written consent for participation in the study.